title: Evaluation of salivary and serum anti-Helicobacter pylori in Egyptian patients with H. pylori related gastric disorders.
abstract: Helicobacter pylori is a common and important transmissible bacterial human pathogen. Although several diagnostic tests are available for the detection of H. pylori infection, all of them have both advantages and disadvantages, and none can be considered as a single gold standard. Serological methods analyzing (serum and saliva) by using enzyme immunoassays, which are simple, reproducible and inexpensive, can detect either antigen or antibody. This study evaluated the frequency of anti- H. pylori serum and salivary antibodies positivity among Egyptian patients with gastric disorders and the validity of salivary, serum serological tests for diagnosis of H. pylori, comparing this with gold standard tests performed on endoscopy biopsy. This prospective, case-controlled study included 45 Egyptian patients who attended Ain Shams University Hospitals Cairo, Egypt between January 2013 and June 2013. There were 29 males &16 females their mean age was 51.78 +/- 7 (range 18-60). Among the ulcerogenic drugs, Aspirin was the most common drug (46.7%). The evidence revealed the sensitivity of Rapid Urease Test (RUT) was 100%, specificity was 71.4%, Positive Predictive value (PPV) was 88.6% and Negative Predictive value (NPV) was 100%. The sensitivity of serum IgG was 68.97% and specificity was 42.86%; while the sensitivity of serum IgA was 89.6% and the specificity was 50%. Correlating the salivary IgG results with H. pylori status diagnosed by culture, salivary IgG succeeded to diagnose 19 cases from the 31 positive H. pylori patients with a sensitivity of 63.33% & specificity of 92.86% whereas the results of salivary IgA showed a sensitivity of 80% and specificity of 92.86%.
authors: Effat Abd El-Monem
authors: EA
authors: El-Fakhfakh
authors: Iman Fawzy
authors: IF
authors: Montasser
authors: Reham Ali Ahmed
authors: RA
authors: Khalifa
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000907:Antibodies, Bacterial / Q000097:blood* / Q000737:chemistry; D000918:Antibody Specificity; D016022:Case-Control Studies; D004534:Egypt / Q000453:epidemiology; D005260:Female; D005767:Gastrointestinal Diseases / Q000382:microbiology*; D016481:Helicobacter Infections / Q000453:epidemiology / Q000276:immunology*; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000737:chemistry; D008297:Male; D008875:Middle Aged; D012463:Saliva / Q000737:chemistry*; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial; D007074:Immunoglobulin G